| Literature DB >> 28721301 |
Mona Piplani1, Harish Rajak2, Prabodh Chander Sharma1.
Abstract
Prodrugs, the inert derivatives of existing drugs have successfully contributed to the modification of their physicochemical properties. The improved antimicrobial potential due to enhanced lipophilicity of some of the synthesized prodrugs of antibacterial agents by various schemes has already been reported. In the current study, synthesis, characterization, and biological evaluation of some more lipid based prodrugs/compounds of ciprofloxacin and norfloxacin has been carried out. The synthesized prodrugs/compounds have been screened for anthelmintic activity using Indian earthworms and cytotoxic activity against human lung cancer cell lines A-549 employing sulforhodamine B (SRB) assay method. The prodrugs FQF1, 6b, 6c, and 6k were found to possess promising anthelmintic activity due to improved partition coefficient. Growth of selected cells lines was found to decrease with increase in concentration of prodrugs as compared to parent drug. Prodrug, 6k having GI50 value 28.8, has been proved to be the most active among all the synthesized prodrugs. Results of present investigation reveal that some of the synthesized prodrugs/compounds were found to possess promising biological activity.Entities:
Keywords: Anthelmintic; Antibacterial; Cytotoxic; Evaluation; Partition coefficient; Prodrug; Synthesis
Year: 2017 PMID: 28721301 PMCID: PMC5491463 DOI: 10.1016/j.jare.2017.06.003
Source DB: PubMed Journal: J Adv Res ISSN: 2090-1224 Impact factor: 10.479
Fig. 1Synthetic scheme 1 for preparation of prodrugs FQF1-FQF4.
Fig. 2Synthetic scheme 2 for preparation of prodrugs 6a-l.
Anthelmintic activity of synthesized prodrugs (FQF1-FQF4).
| Prodrug | Concentration of prodrug (mg/100 mL) | Mean paralysing time (min) ± S.D | Mean death time (min) ± S.D |
|---|---|---|---|
| FQF1 | 200 | 15.50 ± 1.29 | 51.25 ± 1.26 |
| FQF2 | 200 | 21.00 ± 1.83 | 62.00 ± 1.41 |
| FQF3 | 200 | 33.75 ± 1.50 | 75.50 ± 2.08 |
| FQF4 | 200 | 43.25 ± 0.96 | 92.50 ± 1.29 |
| NFX | 200 | 55.75 ± 0.96 | 92.00 ± 2.16 |
| CFX | 200 | 62.75 ± 1.50 | 114.50 ± 1.29 |
| 200 | 15.00 ± 0.82 | 55.25 ± 0.50 | |
| – | – | – |
Each value is mean ± s.d. n = 6.
Albendazole.
DMSO, saline water.
Fig. 3Anthelmintic evaluation of FQF1-FQF4.
Anthelmintic activity of synthesized prodrugs (6a-l).
| Prodrug | Concentration of prodrug (mg/100 mL) | Mean paralysing time (min) ± S.D | Mean death time (min) ± S.D |
|---|---|---|---|
| 6a | 200 | 33.00 ± 1.41 | 73.05 ± 1.29 |
| 6b | 200 | 08.75 ± 0.96 | 20.25 ± 0.96 |
| 6c | 200 | 09.75 ± 0.96 | 36.00 ± 0.82 |
| 6d | 200 | 20.50 ± 1.29 | 57.25 ± 1.71 |
| 6e | 200 | 53.00 ± 1.83 | 63.00 ± 1.63 |
| 6f | 200 | 35.75 ± 1.71 | 86.25 ± 1.50 |
| 6g | 200 | 34.50 ± 1.30 | 49.00 ± 0.82 |
| 6h | 200 | 37.75 ± 1.26 | 84.75 ± 1.26 |
| 6i | 200 | 23.75 ± 1.71 | 51.75 ± 1.71 |
| 6j | 200 | 25.00 ± 0.82 | 45.50 ± 1.73 |
| 6k | 200 | 13.00 ± 0.82 | 39.75 ± 1.71 |
| 6l | 200 | 28.75 ± 1.71 | 62.25 ± 0.96 |
| NFX | 200 | 55.75 ± 0.96 | 92.00 ± 2.16 |
| CFX | 200 | 62.75 ± 1.50 | 114.5 ± 1.29 |
| 200 | 15.00 ± 0.82 | 55.25 ± 0.50 | |
| – | – | – |
Each value is mean ± s.d. n = 6.
Albendazole.
DMSO, Saline water.
Fig. 4Anthelmintic evaluation of prodrugs 6a-l.
GI50 and percentage control growth of synthesized prodrugs.
| Prodrug | Samples ID | Human lung cancer cell line A-549 | GI50 | |||
|---|---|---|---|---|---|---|
| % Control growth Drug concentration in µg/mL (Average values) | ||||||
| 10 | 20 | 30 | 40 | |||
| FQF1 | M1 | 115.0 ± 16.0 | 104.3 ± 13.3 | 105.1 ± 7.4 | 106.5 ± 3.5 | 67.3 |
| FQF2 | M2 | 122.6 ± 22.0 | 125.5 ± 20.2 | 135.9 ± 20.0 | 145.9 ± 23.0 | >80 |
| FQF3 | M3 | 125.2 ± 17.9 | 120.8 ± 18.1 | 126.9 ± 25.0 | 114.2 ± 6.95 | >80 |
| 6a | M4 | 138.2 ± 21.0 | 117.3 ± 16.8 | 103.9 ± 24.5 | 66.9 ± 16.4 | >80 |
| 6b | M5 | 143.4 ± 15.6 | 110.9 ± 17.6 | 96.0 ± 25.0 | 67.6 ± 16.0 | >80 |
| 6f | M6 | 148.6 ± 17 | 139.4 ± 22 | 148.3 ± 19.8 | 172.2 ± 16.2 | >80 |
| 6i | M7 | 95.9 ± 17.9 | 86.5 ± 16.8 | 77.8 ± 19.7 | 45.0 ± 20.6 | 44.5 |
| 6k | M8 | 97.6 ± 4.80 | 95.3 ± 18.5 | 77.7 ± 16.3 | 23.4 ± 8.50 | 28.8 |
| 6l | M9 | 89.3 ± 6.10 | 92.8 ± 22.1 | 76.8 ± 19.1 | 27.4 ± 14.3 | 40.3 |
| Adriamycin | Standard | −33.4 ± 1.9 | −34.1 ± 10.3 | −39.8 ± 6.9 | −30.4 ± 17.8 | <10 |
| Norfloxacin | M10 | 115.7 ± 10.3 | 124.9 ± 18.2 | 120.9 ± 24.0 | 116.6 ± 20.1 | >80 |
Each value is mean ± s.d. n = 3.
Fig. 5Effect of different concentrations of synthesized prodrugs on percentage growth inhibition of Human lung cancer cell A-549.
Fig. 6Effect of different concentrations of synthesized prodrugs on percentage growth inhibition of human lung cancer cell A-549.
Fig. 7Cytotoxic activity of prodrugs M8 (a) and M9 (b) against human lung cancer cell lines.